XOMA Corp (26)

Browse by Contract Category

Contracts

At Market Issuance Sales Agreement, dated August 5, 2021, by and between XOMA Corporation and B. Riley Securities, Inc (Filed With SEC on August 5, 2021)
Royalty Purchase Agreement dated March 22, 2021 between XOMA (US) LLC and Viracta Therapeutics, Inc (Filed With SEC on May 6, 2021)
Amendment No. 1, dated July 24, 2020, to the Non-Exclusive License Agreement, dated November 30, 2001, between XOMA Ireland Limited ("XOMA") and Sesen Bio, Inc (Filed With SEC on March 10, 2021)
Description of Registrants Securities (Filed With SEC on March 10, 2021)
Lease Termination Agreement, dated December 17, 2019, by and between XOMA Corporation and 7th Street Properties II (Filed With SEC on March 10, 2020)
Separation Agreement dated August 31, 2019 between the Company and Dee Datta (Filed With SEC on November 5, 2019)
Settlement and Release Agreement, dated April 15, 2021, by and among XOMA (US) LLC and Affimed N.V., Affimed GmbH Affimed (Filed With SEC on August 5, 2021)
Deposit Agreement, dated effective as of April 9, 2021, by and among the Company, American Stock Transfer & Trust Company LLC, as depositary, and the holders of the depositary... (Filed With SEC on April 8, 2021)
Underwriting Agreement, dated as of April 6, 2021, by and among the Company and B. Riley Securities, Inc., as representative of the several underwriters named therein (Filed With SEC on April 8, 2021)
Amendment No. 1, dated March 10, 2021, to the Common Stock Sales Agreement, dated December 18, 2018, by and between XOMA Corporation and H.C. Wainwright & Co., LLC (Filed With SEC on March 10, 2021)
Non-Exclusive License Agreement, dated November 30, 2001, between XOMA Ireland Limited ("XOMA") Sesen Bio, Inc. and (formerly Viventia Biotech Inc.) (Filed With SEC on March 10, 2021)
Form of Amended and Restated Indemnification Agreement for Directors and Officers (Filed With SEC on March 10, 2021)
Underwriting Agreement, dated as of December 10, 2020, by and between the Company and B. Riley Securities, Inc., as representative of the several underwriters named therein (Filed With SEC on December 11, 2020)
Amendment to Amended and Restated Research, Development and Commercialization Agreement, between the Company and Novartis Vaccine and Diagnostics, Inc., dated September 30, 2015... (Filed With SEC on November 5, 2020)
License Agreement between the Company and Novartis International Pharmaceutical Ltd., dated September 30, 2015 (this exhibit was previously filed under confidential treatment... (Filed With SEC on November 5, 2020)
Amendment No. 3, dated March 31, 2020, to the Common Stock Purchase Agreement, dated December 6, 2017, between XOMA Corporation and Rezolute, Inc. (formerly AntriaBio, Inc.) (Filed With SEC on May 5, 2020)
Collaboration and License Agreement, dated as of March 5, 2020, by and between XOMA (US) LLC and Cadila Healthcare Limited (Filed With SEC on May 5, 2020)
Lease Termination Agreement, dated December 17, 2019, by and between XOMA Corporation and 7th Street Property General Partnership (Filed With SEC on March 10, 2020)
Description of Registrants Securities (Filed With SEC on March 10, 2020)
Investment Agreement, dated November 19, 2019 (Filed With SEC on November 20, 2019)
Royalty Purchase Agreement dated September 26, 2019 between XOMA (US) LLC and Palobiofarma, S.L (Filed With SEC on November 5, 2019)
Royalty Purchase Agreement dated April 7, 2019, between XOMA (US) LLC and Aronora, Inc (Filed With SEC on August 6, 2019)
First Amendment, dated March 4, 2019, to the Loan and Security Agreement dated May 7, 2018, between XOMA Corporation, XOMA (US) LLC and XOMA Technology, Ltd. and Silicon Valley... (Filed With SEC on May 6, 2019)
Form of Warrant (March 2019 Warrant) (Filed With SEC on May 6, 2019)
Amendment No. 2, dated January 7, 2019, to the Common Stock Purchase Agreement, dated December 6, 2017, between XOMA (US) LLC and Rezolute, Inc. (formerly AntriaBio) (Filed With SEC on March 7, 2019)
Amendment No. 2, dated January 7, 2019, to the License Agreement, dated December 6, 2017, between XOMA (US) LLC and Rezolute, Inc. (formerly AntriaBio) (Filed With SEC on March 7, 2019)